Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

por Martin, Matthew J., Eberlein, Cath, Taylor, Molly, Ashton, Susan, Robinson, David, Cross, Darren
Publicado 2016

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance

por Sale, Matthew J., Balmanno, Kathryn, Saxena, Jayeta, Ozono, Eiko, Wojdyla, Katarzyna, McIntyre, Rebecca E., Gilley, Rebecca, Woroniuk, Anna, Howarth, Karen D., Hughes, Gareth, Dry, Jonathan R., Arends, Mark J., Caro, Pilar, Oxley, David, Ashton, Susan, Adams, David J., Saez-Rodriguez, Julio, Smith, Paul D., Cook, Simon J.
Publicado 2019